GlassScriptPhysician profile
Illena Antonetti
NPI 1700990355
$3,836.81
in general payments reported to CMS, 2019-2025
24 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $307 · 2022: $20.42 · 2023: $868 · 2024: $1,655 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $574.34 | 2023-2025 | Assure Wcd |
| Amgen INC. | $366.80 | 2023-2025 | Repatha, Repatha |
| Abbott Laboratories | $329.08 | 2021-2024 | Cardiomems |
| Shockwave Medical, INC | $313.52 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $299.85 | 2021-2023 | Bodyguardian |
| Sanofi-Aventis U.S. LLC | $235.72 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $223.03 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.92 | 2023-2025 | Wainua, Farxiga |
| Medtronic, INC. | $200.97 | 2023-2024 | Venaseal, Hawkone |
| Pfizer INC. | $185.48 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.29 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $143.33 | 2023-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $113.48 | 2024-2025 | Camzyos |
| Atricure, INC. | $70.59 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Abiomed | $62.02 | 2024-2025 | Impella |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $58.18 | 2024 | Arcalyst |
| Medicomp INC | $52.81 | 2023 | Telepatch Cardiac Monitor |
| Inari Medical, INC. | $43.29 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Esperion Therapeutics, INC. | $40.83 | 2024-2025 | Nexletol |
| Philips North America LLC | $35.99 | 2024 | (5091) Amb Mon & Diag Und |
| Scpharmaceuticals INC. | $24.47 | 2024 | |
| Merck Sharp & Dohme LLC | $22.88 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $21.43 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Illena Antonetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.